Skip to Content

'
Kwong K. Wong, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology and Reproductive Medicine - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Kwong K. Wong, Ph.D. is a molecular biologist with extensive experience in cancer genetics and genomics. He has published over 70 peer-reviewed articles and 11 book chapters. He is also an inventor or co-inventor in 6 US issued patents. His laboratory is interested in understanding the molecular pathogenesis of ovarian cancer with a translational goal to identify biomarkers and therapeutic targets for individualized therapy. One of his current projects supported by MD Anderson Ovarian SPORE grant is to understand the progression of low-grade serous ovarian cancer, which typically affects younger women; and patients had a 10-year survival of approximately 30%. Another project is to identify key driver mutations as well as synthetic lethal genes in ovarian cancer cells using a whole genome shRNA and siRNA selection and screening approaches. Dr. Wong is a regular member of the graduate faculty for The University of Texas Graduate School of Biomedical Sciences and train graduate students and clinical fellows.

Research Interest

 1. To understand the molecular pathogenesis in low-grade serous ovarian cancer and develop novel therapeutics. 2) To decipher the molecular mechanisms of chemoresistance in ovarian cancer. 3) To identify synthetic lethal genes in ovarian cancer cells. 4) To analyze extracellular RNA and miRNA in cancer associated stromal cells and cancer cells by Next Generation Sequencing. 5) To develop therapeutics for ovarian clear cell carcinomas.

 

 

Research Interests

Dr. Wong's major area of cancer research is in ovarian cancer and pediatric glioma. He has established several genomics technologies and bioinformatics tools to measure large-scale gene expression profile, promoter methylation, and gene copy number aberration by both Affymetrix GeneChip system and cDNA microarray. Serous ovarian carcinoma represents the major histological subtype of ovarian cancer. The five-year survival rate for patients with late stage disease is less than 20%. A two-tier model has recently been proposed to subdivide serous carcinoma into low- and high-grades. Although patients with low-grade serous ovarian cancers at late stage have better prognoses with five year survival rate approaching 50%, these tumors are the most resistant to chemotherapy. All low-grade tumors are usually well-differentiated and slow-growing. They may share a common molecular mechanism in tumor initiation and progression. A comparative analysis of low-grade ovarian tumor genomic profiles with other low-grade tumors may give us important insight into the underlying molecular mechanism in tumor initiation or progression.

Office Address

Email: kkwong@mdanderson.org

Education & Training

Degree-Granting Education

1990 The Chinese University of Hong Kong, Hong Kong, China, PHD, Biology (Molecular Biology)
1987 The Chinese University of Hong Kong, Hong Kong, China, MPhil, Biology (Bacterial Genetics)
1984 The Chinese University of Hong Kong, Hong Kong, China, BS, Biology/Biochemistry (Hons)

Postgraduate Training

7/1995-6/1996 Research Fellowship, Battelle Memorial Institute, Pacific Northwest National Laboratory, Richland, WA, Dr. Jeffrey Saffer
7/1990-7/1995 Research Fellowship, Genomics, California Institute of Biological Research, La Jolla, CA, Dr. Michael McClelland

Selected Publications

Peer-Reviewed Original Research Articles

1. Mullany LK, Liu Z, Wong KK, Deneke V, Ren YA, Herron A, Richards JS. Tumor Repressor Protein 53 and Steroid Hormones Provide a New Paradigm for Ovarian Cancer Metastases. Mol Endocrinol 28(1):127-137, 1/2014. PMCID: PMC3874458.
2. Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SS, Gershenson DM, Wong KK. KRAS (but not BRAF) mutations in ovarian serous borderline tumor are associated with recurrent low-grade serous carcinoma. J Pathol 231(4). e-Pub 9/14/2013. PMID: 24105490.
3. Wong KK, Izaguirre DI, Kwan SY, King ER, Deavers MT, Sood AK, Mok SC, Gershenson DM. Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 130(3):565-569, 9/2013. PMID: 23800698.
4. Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih IeM, Wong KK, Gershenson DM, Liu J. RAS Promotes Tumorigenesis through Defective Cytokinesis Mediated by Aurora-A and BRCA2. Int J Cancer 133(2):275-85, 7/15/2013. e-Pub 2/12/2013. PMCID: PMC3883442.
5. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-b modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Research 73(16). e-Pub 7/2013.
6. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage High-Grade Serous Ovarian Cancer. Clin Cancer Res 19(4):808-820, 2/15/2013. e-Pub 1/23/2013. PMCID: PMC3577959.
7. Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong KK. PAX2 expression in ovarian cancer. Int J Mol Sci 14(3):6090-6105, 2013. e-Pub 3/15/2013. PMCID: PMC3634442.
8. Mullany LK, Liu Z, King ER, Wong KK, Richards JS. Wild Type Tumor Repressor Protein 53 (TRP53) Promotes Ovarian Cancer Cell survival. Endocrinology 153(4):1638-48, 4/2012. PMCID: PMC3320246.
9. King ER, Zu Z, Tsang YT, Deavers MT, Malpica A, Mok SC, Gershenson DM, Wong KK. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecol Oncol 123(1):13-18, 10/2011. e-Pub 7/2/2011. PMCID: PMC3171566.
10. Mullany LK, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, Anderson ML, Creighton CJ, Xin L, Deavers M, Wong KK, Richards JS. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30(32):3522-3536, 8/2011. e-Pub 3/2011. PMCID: PMC3139785.
11. Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting Src in mucinous ovarian carcinoma. Clin Cancer Res 17(16):5367-5378, 8/2011. PMID: 21737505.
12. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol 35(6):904-912, 6/2011. e-Pub 3/2011. PMCID: PMC3095702.
13. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol 177(4):1611-1617, 10/2010. e-Pub 8/2010. PMCID: PMC2947258.
14. Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep 23(6):1537-43, 6/2010. PMCID: PMC3426036.
15. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16(6):521-32, 12/8/2009. PMCID: PMC3008560.
16. Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG. Breast cancer cells expressing stem cell markers CD44(+) CD24 (lo) are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother 58(8):1185-1194, 8/2009. e-Pub 12/2/2008. PMCID: PMC2726795.
17. Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J, Margolin J, Finegold MJ. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 40(6):843-53, 6/2009. e-Pub 2/5/2009. PMCID: PMC2957366.
18. Wang J, Man TK, Wong KK, Rao PH, Leung HCE, Guerra R, Lau CC. Genome-wide analysis of copy number variations in normal population identified by SNP arrays. The Open Biology J 2(12):54-65, http://www.bentham-open.org/pages/content.2009, 2009.
19. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 22(9):1243-1250, 2009. e-Pub 2009. PMCID: PMC2736318.
20. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. The inflammatory cytokine tumor necrosis factor-alpha confers precancerous phenotype in a organoid model of normal human ovarian surface eipithelial cells. Neoplasia 11(6):529-541, 2009. PMCID: PMC2685442.
21. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437-46, 9/1/2008. PMCID: PMC2766914.
22. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-72, 9/2008. PMCID: PMC2517641.
23. Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, Antalffy BC, Baxter P, Perlaky L, Yang J, Dauser RC, Chintagumpala M, Blaney SM, Lau CC, Li XN. Primary tumor-based orthotopic xenograft mouse models of pediatric brain tumors replicate their biological heterogeneity and preserve cancer stem cell pool during serial in vivo subtransplantations. Stem Cells 26(6):1414-1424, 6/2008. PMID: 18403755.
24. Takei H, Yogeswaren ST, Wong KK, Mehta V, Chintagumpala M, Dauser RC, Lau CC, Adesina AM. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival. J Neurooncol 86(2):183-190, 1/2008. e-Pub 8/10/2007. PMID: 17690840.
25. Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 26(4):404-409, 10/2007. PMID: 17885490.
26. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, Antalffy BA, Blaney SM, Lau CC. Differential expression of surviving splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol 33(1):67-76, 2/2007. PMID: 17239009.
27. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16):2281-7, 2007. PMID: 17538174.
28. Wong KK, Tsang YT, Chang YM, Su J, Di Francesco AM, Meco D, Riccardi R, Perlaky L, Dauser RC, Adesina A, Bhattacharjee M, Chintagumpala M, Lau CC. Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res 66(23):11172-11178, 12/1/2006. PMID: 17145861.
29. Li Y, Wong KK, Matsueda S, Efferson CL, Chang DZ, Ioannides CG, Tsuda N. Mitogen stimulation activates different signaling pathways in early- and late-divided T cells as revealed by cDNA microarray analysis. Int J Mol Med 18(6):1127-39, 12/2006. PMID: 17089018.
30. Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 2006. PMCID: PMC1600675.
31. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res 11(21):7651-7657, 11/1/2005. PMID: 16278384.
32. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of over-expression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11(19):6880-6888, 10/1/2005. PMID: 16203778.
33. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK, Lau CC. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65(18):8142-8150, 9/15/2005. PMID: 16166288.
34. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96(1):77-83, 2005. PMID: 15589584.
35. Wong KK, Chang YM, Tsang YTM, Perlaky L, Su J, Adesina A, Armstrong DL, Bhattacharjee M, Dauser R, Blaney SM, Chintagumpala M, Lau CC. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res 65(1):76-84, 2005. PMID: 15665281.
36. Wong KK, Tsang YTM, Shen J, Cheng RS, Chang YM, Man TK, Lau CC. Allelic imbalance analysis by high-density single nucleotide polymorphic allele (SNP) array with whole genome amplified DNA. Nucleic Acids Res 32(9):e69, 2004. PMCID: PMC419627.
37. Tsang YT, Chang YM, Lu X, Rao PH, Lau CC, Wong KK. Amplification of MGC2177, PLAG1, PSMC6P, and LYN in a malignant mixed tumor of salivary gland detected by cDNA microarray with tyramide signal amplification. Cancer Genet Cytogenet 152(2):124-8, 2004. PMID: 15262430.
38. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao P, Lau CC, Berkowitz RS, Wong KK, Mok SC. Identification of DNA copy-number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 155(2):97-107, 2004. PMID: 15571795.
39. Wong PK, Wong KK, Foote H, Thomas J. Global visualization and alignments of whole bacterial Genomes. IEEE Trans Vis Comput Graph 9(3):361-377, 2003.
40. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9(13):4782-4791, 2003. PMID: 14581349.
41. Wong PK, Wong KK, Foote H. Organic Data Memory Using the DNA Approach. Communications of the ACM 46(1):95-98, 2003.
42. Lipton MS, Pasa-Tolic L, Anderson GA, Anderson DJ, Auberry DL, Battista JR, Daly MJ, Fredrickson JK, Hixson KK, Kostandarithes H, Masselon C, Markillie LM, Moore RJ, Romine MF, Shen Y, Stritmatter E, Tolic N, Udseth HR, Venkateswaran A, Wong KK, Zhao R, Smith RD. Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags. Proc Natl Acad Sci 99(17):11049-11054, 2002. e-Pub 2002. PMCID: PMC129300.
43. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 13(13):1671-1678, 2002. PMID: 11926891.
44. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30(3):670-5, 2001. PMID: 11252802.
45. Mok SC, Chao J, Skates S, Wong KK, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer, identified through microarray technology. JNCI 93(19):1458-1464, 2001.
46. Jensen PK, Pasa-Tolic L, Peden KK, Martinovic S, Lipton MS, Anderson GA, Tolic N, Wong KK, Smith RD. Mass spectrometric detection for capillary isoelectric focusing separations of complex protein mixtures. Electrophoresis 21(7):1372-1380, 2000. PMID: 10826683.
47. Romine MF, Stillwell LC, Wong KK, Thurston SJ, Sisk EC, Sensen C, Gaasterland T, Fredrickson JK, Saffer JD. Complete sequence of a 184-kilobase catabolic plasmid from sphingomonas aromaticivorans F199. J Bacteriol 181(5):1585-602, 1999. PMCID: PMC93550.
48. Wong RMY, Wong KK, Benson NR, McClelland M. Sample sequencing of a salmonella typhimurium LT2 lambda library: Comparison to the E. coli K12 genome. FEMS Microbiology Lett 173(2):411-423, 1999.
49. Markillie LM, Varnum SM, Hradecky P, Wong KK. Targeted mutagenesis by duplication insertion in the radioresistant bacterium Deinococcus radiodurans: radiation sensitivities of catalase (katA) and superoxide dismutase (sodA) mutants. J Bacteriol 181(2):666-9, 1999. PMCID: PMC93425.
50. Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS. DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 16(18):2381-7, 1998. PMID: 9620555.
51. Wong KK, McClelland M, Stillwell LC, Sisk EC, Thurston SJ, Saffer JD. Identification and sequence analysis of a 27-kilobase chromosomal fragment containing a Salmonella pathogenicity island located at 92 minutes on the chromosome map of Salmonella enterica serovar typhimurium LT2. Infect Immun 66(7):3365-71, 1998. PMCID: PMC108353.
52. Wong KK, Markillie LM, Saffer JD. A novel method for producing partial restriction digestion of DNA fragments by PCR with 5-methyl-CTP. Nucleic Acids Res 25(20):4169-71, 1997. PMCID: PMC147012.
53. Mok SC, Chan WY, Wong KK, Muto MG, Berkowitz RS. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12(9):1895-1901, 1996. PMID: 8649850.
54. Wong KK, Stillwell LC, Dockery CA, Saffer JD. Use of tagged random hexamer amplification (TRHA) to clone and sequence minute quantities of DNA--application to a 180 kb plasmid isolated from sphingomonas F199. Nucleic Acids Res 24(19):3778-83, 1996. PMCID: PMC146178.
55. Wong KK, Wong RM, Rudd KE, McClelland M. High-resolution restriction map for a 240-kilobase region spanning 91 to 96 minutes on the Salmonella typhimurium LT2 chromosome. J Bacteriol 176(18):5729-34, 1994. PMCID: PMC196777.
56. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS. Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 52(2):247-252, 1994. PMID: 8314147.
57. Wong KK, McClelland M. Stress-inducible genes of Salmonella typhimurium identified by arbitrarily primed PCR of RNA. Proc Natl Acad Sci 91(2):639-643, 1994.
58. Wong KK, Mok SC, Welsh J, McClelland M, Tsao SW, Berkowitz RS. Identification of differentially expressed RNA in human ovarian carcinoma cells by arbitrarily primed PCR fingerprinting of total RNAs. Int J Oncology 3(1):13-17, 1993.
59. Wong KK, McClelland M. A BlnI restriction map of Salmonella tyhimurium LT2 genome.A BlnI restriction map of Salmonella tyhimurium LT2 genome. J Bacteriol 174(5):1656-1661, 1992.
60. Wong KK, McClelland M. Dissection of Salmonella typhimurium by use of a Tn5 derivative carrying rare restriction sites. J Bacteriol 174(11):3807-3811, 1992.
61. Wong KK, Kwan HS. Transcription of glpT of Escherichia coli K12 is regulated by anaerobiosis and fnr. FEMS Microbiol Lett 94(1-2):15-18, 1992.
62. Wong KK, McClelland M. PCR with 5-methyl-dCTP replacing dCTP. Nucleic Acids Res 19(5):1081-1085, 1991.
63. Wong KK, Suen KL, Kwan HS. Transcription of pfl is regulated by anaerobiosis, catabolite repression, pyruvate, and oxrA: pfl::Mu dA operon fusions of salmonella typhimurium. J Bacteriol 171(9):4900-5, 1989. PMCID: PMC210295.
64. Kwan HS, Chui HW, Wong KK. ack: Mu d1-8 (Apr lac) operon fusions of Salmonella typhimurium LT2. Mol Gen Genet 211(1):183-5, 1988. PMID: 2830464.
65. Kwan HS, Wong KK. A general method for isolation of Mu d1-8 (Aprlac) operon fusions in salmonella typhimurium LT2 from Tn10 insertion strains: chlC: Mu d1-8. Mol Gen Genet 205(2):221-4, 1986. PMID: 3027501.

Invited Articles

1. Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-Grade Serous Carcinoma: New Concepts and Emerging Therapies. Gynecol Oncol 130(3):660-666, 9/2013. e-Pub 5/23/2013. PMID: 23707670.
2. King ER, Wong KK. Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy. Recent Pat Anticancer Drug Discov 7(1):14-30, 1/2012. e-Pub 8/2011. PMID: 21875414.
3. Wong KK. Oral-specific chemical carcinogenesis in mice: an exciting model for cancer prevention and therapy. Cancer Prev Res (Phila) 2(1):10-3, 1/2009. PMID: 19139012.
4. Wong KK. Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway. Recent Pat Anticancer Drug Discov 4(1):28-35, 1/2009. PMID: 19149686.
5. Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 4:27-40, 1/2008. PMID: 19072449.
6. Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96:1-22, 2007. PMID: 17161674.
7. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-376, 2007. PMID: 18057520.
8. Wong KK, Gershenson D. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Dis Markers 23(5-6):377-387, 2007. PMID: 18057521.
9. Wong KK. Rapid partial digestion of DNA fragments by PCR with 5-methyl-dCTP. Promega Notes 73:12-13, 1999.

Abstracts

1. Tsai CC, Zaid TM, Co, CN, Yeung TL, Thompson MS, Carroll A, Yeung ZP, Wong KK, Mok, SC. Expression of interferon-stimulated gene 15 is a novel prognostic predictor for patients with advanced stage high-grade serous ovarian adenocarcinoma. 2011 Proceedings, American Association for Cancer Research 51(408), 2011.
2. Izaguirre D, Zu Z, Tsang-Lee, YT, Mok, S, Wong KK. Induction of GDF15 by cisplatin triggers apoptotic cell death in ovarian cancer cells. 2011 Proceedings, American Association for Cancer Research 51(1708), 2011.
3. King ER, Zu Z, Tsang-Lee YTM, Gershenson DM, Mok, SC, Wong, KK. Insulin-like growth factor-1 is upregulated in low-grade serous ovarian carcinoma. 2011 Proceedings Amercian Association for Cancer Research 51(5031), 2011.
4. King ER, Zu Z, Tsang-Lee YTM, Gershenson DM, Mok, SC, Wong, KK. Regulation of the tumor suppressor gene PAEP in the transition from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. J Clin Oncol 29(5074), 2011.
5. Kwan SY, Fung A, Izaguirre D, Zu Zhifei, Tsang-Lee Y, Mok S, Wong KK. Sensitivity of ovarian clear cell carcinoma cells to P13K inhibitors. 2011 Proceedings, American Association for Cancer Research 51(5037), 2011.
6. Matsuo K, Nishimura M, Stone RL, Komurov K, Shahzad MMK, Bottsford-Miller JN, Enomoto T, Kimura T, Ram PT, Schmeler KM, Frumovits M, Gallick GG, Wong KK, Sood AK. Targeting Src in mucinous ovarian carcinoma. 2011 Proceedings, Amercian Association for Cancer Research 51(5032), 2011.
7. Yeung TL, Ghosh S, Wong KK, Birrer, MJ, Mok SC. Up-regulation of stromal versican in advanced stage serous ovarian cancer modifies tumor microenvironment and promotes cancer invasion. 2011 Proceedings, Americn Association for CAncer Research 51(420), 2011.
8. Yeung ZP, Thompson MS, Yeung TL, Zaid TM, Wong KK, Mok, SC. Uregulation of stromal matrilin-3 expression in advanced stage high-grade serous ovarian cancer. 2011 Proceedings, American Association for Cancer Research 51(1506), 2011.
9. Terashima K, Jsu J, Chow TW, Yu A, Nishikawa R, Matsutani M, Nakamura H, Ng HK, Su J, Bhattacharjee MB, Adekunle A, Wong KK, Leung HE, Man T, Lau CC. Genomic profiling of intracranial germ cell tumors. Neruo-Oncology 12(6):II 104, 6/2010.
10. Mok S, Birrer M, Donninger H, Hao K, Ozbun L, Samini G, Vathepadiekal V, Berkowitz R, Bonome T, Wong KK. A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor:Microfibril-assocated glycoprotein 2. Gynecologic Oncology 116(S164) (#426), 2010.
11. Wong KK, TsangYTM, Deavers MJ, Mok SC, Gersenson DM. Clininical implications of infrequent BRAF mutation in advanced stage low-grade ovarian serous carcinomas. 2010 Proceedings, American Association for Cancer Research 51 (#2129A), 2010.
12. Yeung T, Ghosh S, Wong KK, Gutierrez-Hartman A, Kwong J, Welch W, Gershenson D, Birrer M, Mok SC. Differential nuclear Elf-3 expression in high-grade serous ovarian cancer is associated with patient survival. Gynecologic Oncology 116(S17) (#40), 2010.
13. Yeung TL, Wong KK, Gutierrez-Hartmann A, Kwong J, Welch WR, Gershenson DM, Birrer MJ, Mok SC. Elf3 as negative regulation for epithelial-mesenchymal transition in ovarian cancer. 2010 Proceedings, American Association for Cancer Research 51 (#3298), 2010.
14. Zaid T, Thompson, M, Wong KK, Yeung T, Yates M, Mirrer M, Mok SC. Identification of FGFR4 in the chromosome 5q31-35 prognostic amplicon as the mediator for FGF-1 signaling in high-grade serous ovarian cancer. Gynecologic Oncology 116(S125) (#320), 2010.
15. Thompson MS, L Albitar, Ghosh S, Wong KK, Welch WR, Birrer MJ, Mok SC. Identification of secretory stromal gene signature of the ovarian tumor microenvironment and implications for ovarian cancer progression. 2010 Proceedings, American Association for Cancer Research 51 (#1426), 2010.
16. Thompson M, Albitar L, Ghosh S, Wong KK, Welsch W, Birrer MJ, Mok SC. Identification of secretory stromal gene signature of the ovarian tumor microenvironment and implications for ovarian cancer progression. Gynecologic Oncology 116(S129) (#330), 2010.
17. Wong K, Tsang Y, Zu Z, Mok S, Deavers MT, Birrer MJ, Wolf J, Lu KH, Gershenson DM. Insulin growth factor 1 pathway is a potential therapeutic target for low-grade ovarian serous carcinomas. Gynecologic Oncology 116(S113) (#290), 2010.
18. Song H, Tung CS, Tsang Y, Mok SC, Gershenson DM, Wong KK. PAX2 is an oncogene in type 1 ovarian cancer. 2010 Proceedings, American Association for Cancer Reserach 51 (#363A), 2010.
19. Zaid T, Thompson MS, Wong KK, Yeung TS, Yeung Z, Yates MS, Birrer MJ, Mok SC. Proliferative effects of FGF1 on ovarian cancer cells correlate with FGFR4 over expression and are mediated by MAPK/ERK signaling. 2010 Proceedings, American Associaton for Cancer Research 51 (#3132), 2010.
20. Chan PK, Wong KK. Anti-tumor activities of a saponin(Y3) on ovarian cancer cells. Proc Amer Assoc Cancer Res 50(167), 2009.
21. Mok. SC, GHos S, Kwong J, Welch WR, Gershenson D, Birrer MF, Wong KK. Differential nuclear Elf-3 expression in high-grade serous ovarian cancer is associated with patient survival. 2009 Proceedings, American Association for Cancer Research 50(655), 2009.
22. Wong KK, Tung CS, Yeung C, Zu Z, Tsang YTM, Deavers M, Wolf J, Birrer MJ, Lu KH, Mok SC, Gershenson DM. Decreased expression of BCMP11 during progression from LMP to low-grade ovarian serous carcinoma. The 39th Annual Meeting of the Society of Gynecologic Oncologists 115, 2008.
23. Albetar L, Wong KK, Shosh S, Bonome T, Birrer MJ, Mok SC. Identification of a stem-cell related gene signature in the stroma of high-grade advanced stage serous ovarian cancer. Proc Amer Assoc Cancer Res 49:3434, 2008.
24. Tung CS, Yeung CS, Mok SC, Birrer MJ, Lu KH, Gershenson DM, Wong KK. The Role of PAX2 as a Potential Biomarker of Low-Grade Serous Ovarian Carcinoma. SGO 2008 Winter Meeting 1339, 2008.
25. Tung CS, Yeung CS, Mok SC, Birrer MJ, Lu KH, Gershenson DM, Wong KK. The Role of PAX2 as a Potential Biomarker of Low-Grade Serous Ovarian Carcinoma. The 39th Annual Meeting of the Society of Gynecologic Oncologists 129, 2008.
26. Wong KK, Tsang YTM, Gu Y, Lu KH, Deavers M, Malpica A, Gershenson DM. High-resolution global genomic analysis of low-grade serous ovarian tumors reveals novel regions of allelic imbalances. The 38th Annual Meeting of the Society of Gynecologic Oncologists 94, 2007.
27. Tsang YTM, Zhou Z, Lau CC, Wong KK. Over-expression of Semaphorin 3E and 5A in juvenile pilocytic astrocytomas. The 12th Scientific Meeting of the Society for Neuro-Oncology PB-17, 2007.

Book Chapters

1. Erin R. King and Kwong-Kwok Wong. Steroid hormones and ovarian cancer. In: Steriods - Clinical Aspect. Ed(s) H Abduljabbar. In-Tech, http://www.intechopen.com/books/steroids-clinical-aspect/steroid-hormones-and-ovarian-cancer, e-Book 2011. ISBN: 978-953-307-705-5.
2. Tung CS, Wong KK,. Molecular signatures in ovarian cancer. In: Field Cancerization: Basic Science and Clinical Applications. Ed(s) GD Dakubo. Nova Science Publishers, Inc: New York, Chapter 21, 2010. ISBN: 978-1-61761-386-9.
3. Wong KK. Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers. In: Pharmacogenomics, Anticancer Drug Discovery and Response. Ed(s) Innocenti F. Humana Press: Totowa, NJ, 2007.
4. Wong KK, Kanno J, Cheng RS, Sasser L, Morris J, Anderson L, Pounds J, Inoue T. Application of cDNA microarray for uterotrophic assay. In: Toxicogenomics. Ed(s) Inoue T, Pennie WD. Springer-Verlag: Tokyo, Japan, 2003.
5. Wong KK, Chen RS, Kim JH, Mok SC. Gene expression analysis of ovarian tumors with a cDNA microarray containing ovarian tumor specific clones. In: Perspective in Gene Expression. Ed(s) Appasani K. Eaton Publishing: Natick, MA, 2003.
6. Wong KK, Cheng RS, Berkowitz RS, Mok SC. Gene expression analysis of ovarian cancer cells by CDNA microarray. In: Microarray and Cancer. Ed(s) Warrington J, Todd CR, Wong D. Eaton Publishing: Natick, MA, 2002.
7. Mok SC, Wong KK, Chan WY, Lau CC, Sager R, Berkowitz RS. Changes in gene expression. In: Ovarian Cancer. 5. Ed(s) Sharp F, Blackett T, Berek J, Bart R. Isis Medical Media Ltd. Oxford, UK, 25-33, 1998.
8. McClelland M, Wong KK, Sanderson KE. Physical Mapping and Fingerprinting of Bacterial Genomes using rare cutting restriction enzymes. In: Bacterial Genomes: Physical Structure and Analysis. Ed(s) deBruijn F, Lupski J, Weinstock G. Chapman and Hall, 1998.
9. Wong KK, Cheng R, Saffer JD, Ralph D, Welsh J, McClelland M. DNA fingerprinting by arbitrarily primed PCR (RAPDs). In: Molecular Microbial Ecology Manual. Ed(s) Akkermans ADL, van Elsas JD, de Bruijn FJ. Kluwer Academic Publishers: THe Netherlands, 1-14, 1996.
10. Liu SL, Wong KK, McClelland M, Sanderson KE. Construction of a physical map of the genome of Salmonella typhimurium. In: The Biology of Salmonella. Ed(s) Cabello F, Hormaeche C, Mastroeni P, Bonina L. Plenum Press: New York, 41-50, 1993.
11. Wong KK, Kwan HS. A novel mutation causing deficiency in lactate production of Salmonella typhimurium during mixed acid fermentation. In: Recent Advances in Applied Biology and Biotechnology. Ed(s) Chang ST, Chan KY, Woo NYS. CUHK Press, 293-300, 1988.
 

Other

1. Interview. Affymetrix Microarray Bulletin, "New Copy Number Algorithm Developed at University of Tokyo" Interview with Dr. Aburatani, April 2005.

Grant & Contract Support

Title: ISG15 in ovarian cancer progression
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Wong
Duration: 7/1/2014 - 6/30/2019
 
Title: Targeted Therapy for Ovarian Clear Cell Carcinoma
Funding Source: Marsha Rivin Center for Ovarian Cancer Research
Role: Principal Investigator
Duration: 4/1/2014 - 3/31/2015
 
Title: Genomic stratification of ovarian cancer patients
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Michael Birrer
Duration: 9/27/2010 - 11/30/2013
 
Title: Project 3b: Personalized therapies for low-grade ovarian serous carcinomas
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Robert C. Bast, Jr., MD
Duration: 9/1/2010 - 8/31/2015
 
Title: Novel Angiogenic Factor in Ovarian Cancer Microenvironment
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: SC Mok
Duration: 4/1/2010 - 10/30/2013
 
Title: Insulin-like growth factor 1 (1GF1) pathway as potential therapeutic target for low-grade ovarian serous carcinoma
Funding Source: Health, Empowerment, Research and Awareness (HERA)
Role: Principal Investigator
Duration: 4/1/2010 - 3/31/2011
 
Title: Prognostic Markers for Ovarian Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Samuel Mok
Duration: 4/1/2009 - 12/31/2013

Last updated: 5/20/2014